Completed NA INTERVENTIONAL 4-arm NCT00214019

The Effect of Salmeterol on Eosinophil (EOS) Function

Sponsor: GlaxoSmithKline

Interventions Fluticasone Placebo salmeterol

Updated 8 times since 2017 Last updated: Oct 17, 2017 Started: Nov 30, 2003 Primary completion: Jan 31, 2008 Completion: Jan 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00214019, this NA trial focuses on Allergic Asthma and remains completed. Sponsored by GlaxoSmithKline, it has been updated 8 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Dec 2021 — Jul 2024 [monthly]

Completed NA
Jan 2021 — Dec 2021 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA

▶ Show 3 earlier versions

Dec 2017 — Jun 2018 [monthly]

Completed NA
Feb 2017 — Dec 2017 [monthly]

Completed NA
Jan 2017 — Feb 2017 [monthly]

Completed NA

First recorded

Nov 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
University of Wisconsin, Madison

Data source: University of Wisconsin, Madison

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Madison, United States